公开(公告)号：US20240365665A1

公开(公告)日：2024-10-31

申请号：US18765825

申请日：2024-07-08

Applicant: Universal Display Corporation

Inventor： Hsiao-Fan Chen ,  Tongxiang (Aaron) Lu ,  Nicholas J. Thompson ,  Eric A. Margulies ,  George Fitzgerald ,  Jerald Feldman

IPC: H10K85/60 ,  C07D209/86 ,  C07D265/38 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  C07D487/04 ,  C09K11/06 ,  H10K50/11 ,  H10K101/10

CPC classification number: H10K85/6572 ,  C07D209/86 ,  C07D265/38 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  C07D487/04 ,  C09K11/06 ,  H10K85/615 ,  H10K85/622 ,  H10K85/623 ,  H10K85/624 ,  H10K85/626 ,  H10K85/631 ,  H10K85/633 ,  H10K85/636 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6576 ,  C09K2211/1018 ,  H10K50/11 ,  H10K2101/10

Abstract: Compounds that are organic radicals that can have a dual function. The compounds can be fluorescent emitters that emit in the near-IR. The compounds can also facilitate reverse intersystem crossing (RISC) to convert triplet excitons in an OLED to singlet excited states to maximize utilization of generated excitons in the OLED and approach 100% internal quantum efficiency.

公开(公告)号：US20240336594A1

公开(公告)日：2024-10-10

申请号：US18576708

申请日：2022-06-24

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Qichao SHEN ,  Guolong DU ,  Xiaojun ZHOU ,  Yun SUN ,  Yuzhen ZHOU ,  Xiao SUN ,  Weidong CAI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

公开(公告)号：US20240327392A1

公开(公告)日：2024-10-03

申请号：US18573760

申请日：2022-06-24

Applicant: ALBIUS SCIENCES ALPHA PRIVATE LIMITED

Inventor： Shigeru MATSUOKA ,  Hiroshi TSUCHIKAWA ,  Kentaro YAMADA ,  Akira KATO

IPC: C07D413/04 ,  C07D413/14 ,  C07D471/08

CPC classification number: C07D413/04 ,  C07D413/14 ,  C07D471/08

Abstract: The present invention provide compounds useful for treating and/or preventing RS virus infections.
The present invention relates to compounds represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:






wherein Y1, Y2, Y3 and X4 and so on are as defined in the specification;
as well as a use of the compounds for treating and/or preventing RS virus infections, and pharmaceutical compositions comprising those compounds.

公开(公告)号：US20240327361A1

公开(公告)日：2024-10-03

申请号：US18546322

申请日：2022-02-15

Applicant: The Research Foundation for the State University of New York

Inventor： Nashaat Turkman

IPC: C07D271/06 ,  A61K31/4025 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/04 ,  C07D413/12

CPC classification number: C07D271/06 ,  A61K31/4025 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides a compound which is a class-lla histone deacetylases (HDAC) inhibitor, a process of making the compound, a composition containing the compound and radiolabeling the compound for use in positron emission tomography (PET) imaging, said compound having the structure:

公开(公告)号：US20240317765A1

公开(公告)日：2024-09-26

申请号：US18629703

申请日：2024-04-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi HATTORI ,  Marilena PIRA ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Eiji KIMURA ,  Norihito TOKUNAGA ,  Shuhei IKEDA ,  Martin Alexander PAWLICZEK ,  Noriyuki TEZUKA ,  Yasutaka HOASHI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE

IPC: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20240308983A1

公开(公告)日：2024-09-19

申请号：US18644412

申请日：2024-04-24

Applicant: Aptabio Therapeutics Inc.

Inventor： Soo Jin LEE ,  Sung Hwan MOON ,  Sooho BAN ,  Eunsil LEE ,  Eun Jung SHIN ,  Yoo-Kyung GOH

IPC: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

CPC classification number: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.




(In the above, A, B and R, and the like are the same as defined in the description of the invention.)

公开(公告)号：US20240308960A1

公开(公告)日：2024-09-19

申请号：US18563776

申请日：2022-05-26

Applicant: Sumitomo Pharma Co., Ltd.

Inventor： Masafumi KOMIYA ,  Shunichiro UESUGI ,  Eiji IDEUE ,  Shoukou LEE ,  Daisuke TANAKA ,  Yuta FUNAKOSHI

IPC: C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

CPC classification number: C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

Abstract: The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin receptor type 2, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing a disease such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome.

公开(公告)号：US20240300938A1

公开(公告)日：2024-09-12

申请号：US18649184

申请日：2024-04-29

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Bertrand LE BOURDONNEC ,  Matthew LUCAS ,  Kerem OZBOYA ,  Bhaumik PANDYA ,  Parcharee TIVITMAHAISOON ,  Iwona WRONA

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

公开(公告)号：US20240300930A1

公开(公告)日：2024-09-12

申请号：US18548119

申请日：2022-02-28

Applicant: MSN LABORATORIES PRIVATE LIMITED, R&D CENTER

Inventor： Thirumalai Rajan SRINIVASAN ,  Eswaraiah SAJJA ,  Rajeshwar Reddy SAGYAM ,  Navin Kumar Reddy KESHAVAREDDY ,  Ananthan BAKTHAVACHALAM

IPC: C07D413/04 ,  A61K31/4439

CPC classification number: C07D413/04 ,  A61K31/4439

Abstract: The present invention relates to a novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide of formula (I)




The present invention also relates to the novel intermediate compounds of formula (V), formula (VII), and their processes for the preparation thereof.
The present invention also relates to the use of compounds of formula (V), formula (VII) intermediate in the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1, 2, 4-oxadiazol-3-yl)-4, 6-dimethylpyridine-1-oxide of formula (I).

公开(公告)号：US20240299385A1

公开(公告)日：2024-09-12

申请号：US18561189

申请日：2022-06-03

Applicant: ReWind Therapeutics NV

Inventor： Vincent Pericolle ,  Jean-Christophe Vanherck ,  Arnaud Didier Marie Marchand ,  Guillaume Albert Jacques Duvey ,  Rui Miguel Garcia Costa Pinto

IPC: A61K31/506 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28 ,  C07D207/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: A61K31/506 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28 ,  C07D207/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and/or as diagnostics. The present invention also relates to the present compounds for use in the prevention and/or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.